DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Xigris (Drotrecogin Alfa (Activated)) - Summary

 
 



XIGRIS SUMMARY

Xigris® (drotrecogin alfa (activated)) is a recombinant form of human Activated Protein C. An established human cell line possessing the complementary DNA for the inactive human Protein C zymogen secretes the protein into the fermentation medium. Fermentation is carried out in a nutrient medium containing the antibiotic geneticin sulfate. Geneticin sulfate is not detectable in the final product. Human Protein C is enzymatically activated by cleavage with thrombin and subsequently purified.

Xigris is indicated for the reduction of mortality in adult patients with severe sepsis (sepsis associated with acute organ dysfunction) who have a high risk of death (e.g., as determined by APACHE II, see CLINICAL STUDIES).

Safety and efficacy have not been established in adult patients with severe sepsis and lower risk of death (see CLINICAL STUDIES, Long-Term Follow-Up). Safety and efficacy have not been established in pediatric patients with severe sepsis.


See all Xigris indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Xigris (Drotrecogin Alfa)

Rapid test to diagnose severe sepsis
Source: Blood / Hematology News From Medical News Today [2014.10.24]
A new test, developed by University of British Columbia researchers, could help physicians predict within an hour if a patient will develop severe sepsis so they can begin treatment immediately.

Stroke, Sepsis, Opiates: ACEP 2014
Source: MedPage Today Cardiovascular [2014.10.23]
(MedPage Today) -- Meeting highlights from the research forum chairman.

Penn Medicine's 'sepsis sniffer' generates faster sepsis care and suggests reduced mortality
Source: Blood / Hematology News From Medical News Today [2014.10.12]
An automated early warning and response system for sepsis developed by Penn Medicine experts has resulted in a marked increase in sepsis identification and care, transfer to the ICU, and an...

New research suggests treatment in Australia and New Zealand for patients with sepsis is the best in the world
Source: Blood / Hematology News From Medical News Today [2014.10.06]
Australia's high survival rates shed doubt on global sepsis guidelines.The large-scale six-year study, led by the Australian and New Zealand Intensive Care Research Centre at Monash University...

New toolkit will help doctors recognise and treat sepsis
Source: Nursing / Midwifery News From Medical News Today [2014.09.03]
A new toolkit from the Royal College of Physicians (RCP) and The UK Sepsis Trust will help doctors recognise and treat sepsis on acute care wards.

more news >>

Published Studies Related to Xigris (Drotrecogin Alfa)

Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism. [2011]
INTRODUCTION: There are no published data on the status of endogenous activated protein C (APC) in pulmonary embolism (PE), and no data on the effect of drotrecogin alfa (activated) (DAA) given in addition to therapeutic dose enoxaparin... CONCLUSIONS: In patients with acute submassive PE endogenous APC levels are low. DAA infusion enhances the inhibition of fibrin formation. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00191724.

Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated). [2010]
INTRODUCTION: Serial alterations in protein C levels appear to correlate with disease severity in patients with severe sepsis, and it may be possible to tailor severe sepsis therapy with the use of this biomarker. The purpose of this study was to evaluate the dose and duration of drotrecogin alfa (activated) treatment using serial measurements of protein C compared to standard therapy in patients with severe sepsis... CONCLUSIONS: The study met its primary objective of increased protein C levels in patients receiving alternative therapy demonstrating that variable doses and/or duration of drotrecogin alfa (activated) can improve protein C levels, and also provides valuable information for incorporation into potential future studies. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00386425.

A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: Comparison with a controlled clinical trial. [2008.01]
OBJECTIVE:: To compare characteristics and outcomes of patients treated with drotrecogin alfa (activated) (DrotAA) in clinical practice to those treated in a phase III randomized controlled trial (PROWESS)... CONCLUSIONS:: Patients treated in clinical practice differed from those in PROWESS. Patients were younger, had more comorbidities, had greater severity of illness, and had longer mean time from severe sepsis onset to the start of DrotAA. Hospital mortality for patients treated within 1 day of severe sepsis onset was similar to DrotAA-treated PROWESS patients. While the low number of serious bleeding events precludes a definitive assessment, the observed incidence of serious bleeding events in clinical practice patients was numerically higher than in DrotAA-treated PROWESS patients.

My brother has severe sepsis Should he receive Xigris(R)? [2007.12]
Six years ago, a publication in a quite well known scientific medical journal brought hope and a good dose of optimism to sepsis therapy and the critical care community. For the first time, a careful randomized controlled trial in patients with severe sepsis or septic shock seemed to show a clearly beneficial effect of a new drug, i.e...

Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). [2007.09.01]
RATIONALE: Patients with severe sepsis frequently receive prophylactic heparin during drotrecogin alfa (activated) (DrotAA) treatment due to risk of venous thromboembolic events (VTEs). Biological plausibility exists for heparin to reduce DrotAA efficacy and/or increase bleeding. OBJECTIVES: Primary: demonstrate in adult patients with severe sepsis receiving DrotAA treatment that 28-day mortality was equivalent for patients treated with concomitant prophylactic heparin compared with placebo; secondary: safety and VTE incidence... CONCLUSIONS: Compared with placebo, concomitant prophylactic heparin was not equivalent, did not increase 28-day mortality, and had an acceptable safety profile in patients with severe sepsis receiving DrotAA. Heparin discontinuation should be carefully weighed in patients considered for DrotAA treatment. XPRESS clinical trial registered with www.clinicaltrials.gov (NCT 00049777). The study ID numbers are 6743; F1K-MC-EVBR.

more studies >>

Clinical Trials Related to Xigris (Drotrecogin Alfa)

Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis [Completed]
The purposes of this study are to determine:

1. Whether drotrecogin alfa (activated) helps children with severe sepsis survive their condition more often or recover faster than children who do not receive drotrecogin alfa (activated).

2. Whether drotrecogin alfa (activated) minimizes long term disabilities associated with severe sepsis.

3. The side effects that might be associated with drotrecogin alfa (activated) administration to children with severe sepsis.

Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study [Completed]

A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation [Completed]
The purpose is to determine how Drotrecogin Alfa (activated) will affect patients with blood cancers who develop severe sepsis within 60 days of starting chemotherapy in preparation for bone marrow transplant (BMT).

Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated) [Recruiting]
Protein C is a protein that is involved in your body's ability to clot blood. In this trial, patients with severe sepsis and low protein C levels will receive drotrecogin alfa (activated) at the normal, approved dose and time of administration [24mcg/kg/hour for 96 hours] or will receive the normal, approved dose or higher doses than the approved dose for a longer administration time. After the drug administration is complete, the protein C levels from the patients receiving the normal, approved dose will be compared to protein C levels from patients receiving the normal, approved dose or higher dose for a longer duration to determine if the protein C levels improve faster if given higher dose and/or longer administration time.

Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion [Completed]
The purpose of this study is to determine whether continued administration of Drotrecogin

Alfa (Activated) up to additional 72 hours - after the so far recommended 96 hour infusion

period - results in a more rapid resolution of hypotension in severe septic patients.

more trials >>

Reports of Suspected Xigris (Drotrecogin Alfa) Side Effects

Brain Death (2)Death (2)Finger Amputation (2)Brain Oedema (2)Immune System Disorder (2)Septic Shock (2)Disseminated Intravascular Coagulation (1)Cerebral Haemorrhage (1)Multi-Organ Failure (1)Myocardial Infarction (1)more >>


Page last updated: 2014-10-24

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014